{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Investing in Impact | Impact Investing","title":"Inside Lupus Ventures and the Push to Fund Cures First","html":"","width":"100%","height":180,"duration":386,"description":"For decades, lupus has remained one of the most complex challenges in modern medicine. Its extreme heterogeneity, where symptoms and triggers can vary widely from one patient to the next, has made the disease difficult to study, diagnose, and treat.\n\nAs a result, lupus has often been passed over by traditional venture capital in favor of conditions with more predictable development paths.\n\nThat dynamic is now beginning to change.\n\nA growing wave of scientific advances, regulatory progress, and an increasingly active clinical pipeline is signaling a turning point for millions of patients worldwide.\n\nAt the center of this shift is Lupus Ventures, a mission driven investment fund launched by the Lupus Research Alliance.\n\nThe fund combines the discipline of life sciences venture capital with a clear focus on return on mission, aiming to close the funding gap that has long stalled promising breakthroughs in autoimmune disease research.\n\nIn this spotlight, we speak with Nishant Rastogi, Managing Director of Lupus Ventures.\n\nDrawing on more than a decade of experience in biotech private equity and venture capital, Nishant explains why he chose to lead a mission driven fund, why early diagnostics are critical to improving patient outcomes, and how Lupus Ventures is helping reshape how cures are funded for historically underserved diseases.\nFull interview","thumbnail_url":"https://img.transistorcdn.com/xH2V0wRai2vSs5BEN2Ofr_Xx5JRthVsX0ReYVPkrd1k/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8xZmE5/Y2UyMDQzMGQwZGMx/YmI2ZjgyOTViYzcy/MTViMC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}